CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In this trial, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more in patients with high-risk muscle-invasive urothelial carcinoma who had had radical surgery.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
